American Journal of Epidemiology Vol. 119, No. 4: 591-602
Copyright © 1984 by The Johns Hopkins University School of Hygiene and Public Health
other |
IMMUNOLOGIC RESPONSIVENESS AND SAFETY ASSOCIATED WITH THE COCCIDIOIDES IMMITIS SPHERULE VACCINE IN VOLUNTEERS OF WHITE, BLACK, AND FILIPINO ANCESTRY
1Department of internal Medicine, Naval Hospital Lemoore, CA
2Division of Infectious Diseases, Santa Clara Valley Medical Center, and Institute for Medical Research San Jose, CA
3Division of Infectious Diseases, Department of Medicine, Stanford University School of Medicine Stanford, CA
4Department of Preventive Medicine, Naval Hospital Lemoore, CA
5Department of Medical Microbiology, University of California Medical School Davis, CA
6Naval Biosciences Laboratory, School of Public Health, University of California Berkeley, CA
7Naval Dispensary Treasure Island, CA Naval Regional Medical Center Oakland, CA
8Division of Biostatistics, Department of Family, Community, and Preventive Medicine, Stanford University School of Medicine Stanford, CA
9Department of Pathology, Stanford University School of Medicine Stanford, CA
10Reprint requests to Dr. D. A. Stevens, Department of Medicine, Santa Clara Valley Medical Center, 751 S. Bascom Ave., San Jose, CA 95128.
A trial of the killed Coccidioides immitis spherule vaccine was undertaken with 151 healthy skin test negative adult volunteers and controls to evaluate the safety of selected regimens, the induction of humoral and cell-mediated immune responses, and to determine if there were immunogenetic differences in these responses. The vaccine was given as three intra-deltoid doses over 8 weeks. No severe systemic symptoms were noted, although 3% of 3.5 mg doses (but no 1.75 mg doses) were associated with severe local reactions. Half the vaccinees had skin test conversions, which generally persisted
6 months, two-thirds showed boosting of lymphocyte transformation in vitro, and 16% given three 3.5 mg doses developed antibody. There was an association between degree of local adverse vaccine reaction and immunostimulation, and a trend to immune response in persons of O blood type and with some HLA phenotypes. There was no evidence of deficient response to vaccination in subpopulatlons known to respond to coccidioidal infection poorly. A regimen of three 1.75 mg doses appears to be safe and without reduced Immunogenicity, and there is no evidence dosage modification for certain subpopulatlons would be necessary in efficacy studies.
antigens, fungal; coccidioides; coccidioidomycosis; fungal vaccines; immunogenetics; mycology; vaccines
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
R. A. Cox and D. M. Magee Coccidioidomycosis: Host Response and Vaccine Development Clin. Microbiol. Rev., October 1, 2004; 17(4): 804 - 839. [Abstract] [Full Text] [PDF] |
||||
